Therapy of mantle cell lymphoma: current standards and future strategies.
Mantle cell lymphoma is characterized clinically by an aggressive clinical course and is relatively resistant to conventional chemotherapies. When in its advanced stages, currently available immunochemotherapy regimens remain noncurative despite high initial response rates. In contrast, consolidating high-dose therapy with autologous stem cell retransfusion significantly extends progression-free survival of young patients. Currently, allogenic bone marrow transplantation represents the only therapy with the potential for a curative approach, although associated with a high rate of complications. New concepts of therapy are urgently warranted, including new molecular approaches, such as bortezomib, thalidomide, lenalidomide, and temsirolimus.
Schmidt
Christian
C
Department of Medicine III, University of Munich, Hospital Grosshadern, Marchioninistrasse 15, D-81377 Munich, Germany.
Dreyling
Martin
M
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging / Q000379:methods; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents